Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhenguang https://orcid.org/0000-0002-8317-3163
Kean, Iain R. L. https://orcid.org/0000-0003-1066-8285
Dratva, Lisa M. https://orcid.org/0000-0002-2873-6787
Clark, John A. https://orcid.org/0000-0001-6916-9195
Syrimi, Eleni
Khan, Naeem
Daubney, Esther
White, Deborah
O’Neill, Lauran
Chisholm, Catherine
Payne, Caroline
Benkenstein, Sarah
Kupiec, Klaudia https://orcid.org/0000-0002-5673-173X
Galassini, Rachel
Wright, Victoria https://orcid.org/0000-0001-7826-1516
Winmill, Helen
Robbins, Ceri
Brown, Katherine
Ramnarayan, Padmanabhan
Scholefield, Barnaby https://orcid.org/0000-0002-6198-4985
Peters, Mark
Klein, Nigel https://orcid.org/0000-0003-3925-9258
Montgomery, Hugh
Meyer, Kerstin B. https://orcid.org/0000-0001-5906-1498
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Bryant, Clare https://orcid.org/0000-0002-2924-0038
Taylor, Graham https://orcid.org/0000-0002-4807-2797
Pathan, Nazima https://orcid.org/0000-0002-9447-4252
-
Funding
Funding for this research was provided by:
Action Medical Research
CUH | Addenbrooke’s Charitable Trust, Cambridge University Hospitals
- License Information
-
More Information
Article History
Received: 31 October 2022
Accepted: 10 May 2024
First Online: 18 May 2024
Competing interests
: In the past three years, S.A.T. has received remuneration for Scientific Advisory Board Membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity in Transition Bio. C.E.B. is on the SAB of NodThera, Lightcast, Related Sciences and Janssen Pharmaceuticals and is a co-founder of Polypharmakos and Danger Bio. N.P. received an honorarium from Biomerieux Diagnostics. The other authors declare no competing interests.
